Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Cancer Vaccine (PCV) Strategy in Solid Tumors and Molecular Residual Disease
NCT06529822Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2025
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial in bladder carcinoma, gastroesophageal adenocarcinoma, melanoma and 1 more (4 cohorts), sponsored by Washington University School of Medicine. Primary endpoints: Treatment-Emergent Adverse Events at 13 months, Treatment-Related Adverse Events at 13 months and 4 more. Started Mar 2025; status: recruiting.
02
Conditions
bladder carcinomagastroesophageal adenocarcinomamelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06529822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06529822.